drugset / Trial / NCT07347444
Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab, in combination with bevacizumab, albumin-bound paclitaxel, and carboplatin as first- or second-line treatment in patients with acral and mucosal melanoma.
Timeline
- Start
- 2026-02
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Tuvoraleimab | Unknown | 5 mg/kg | — |
| Background | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Background | Carboplatin | Small molecule | 2 unknown | — |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |